Compare Johnson & Johnson (JNJ) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Msci Inc — how do they compare? Johnson & Johnson trades at $249.28 (market cap $598.96B), while Msci Inc trades at $559.14 (market cap $45.51B). The key difference: Johnson & Johnson is far larger — about 13.2× Msci Inc's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | MSCI | |
|---|---|---|
Market Cap | $598.96B | $45.51B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $643.83 |
52-Week Low | $164.36 | $511.84 |
Enterprise Value | $631.90B | $51.67B |
Dividend Yield | 2.15% | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
MSCI trades at $625.11, down 0.56% on the day, with a bullish technical outlook supported by moving averages and a recent strategic partnership with UBS to enhance its private markets platform. The company shows strong fundamentals with a 40.74% net income margin and consistent earnings beats, though valuation ratios like a P/E of 35.9 suggest a premium. Analyst consensus is strongly bullish with a $723.38 price target, and cash flow turned positive in 2025 after prior years of net outflows.
The outlook for MSCI is positive, driven by earnings growth, high profitability, and strategic expansions, but risks include elevated debt levels and sensitivity to financial market conditions. The stock offers a dividend yield supported by solid cash generation, though investors should weigh the high valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
